Moderna, COVID
Moderna’s COVID vaccine sales plunge, as analysts debate future of once-hot company
Plunging sales of Moderna’s breakthrough COVID-19 vaccine have touched off a Wall Street debate about the future of a biotech company once seen as the brightest star in the Massachusetts drug-making firmament.
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
Moderna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine topped estimates.  The results come as Moderna inches closer to having another product on the market,
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
The drugmaker is optimistic about higher sales with new vaccines and a little help from AI in the coming years.
Moderna COVID vaccine sales plummet 91 percent
Sales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter in a dramatic illustration of waning demand for protection from the virus that caused the pandemic.
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Moderna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech giant’s cost-cutting helped offset a steep decline in its Covid business.
Moderna quarterly sales beat expectations but plummet from previous year
Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher. Sales of Moderna’s COVID-19 shot Spikevax,
Moderna's Options Frenzy: What You Need to Know
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Business Insider21h
Maintaining Hold on Moderna: Balancing Strong Q1 Sales with Future Uncertainties and Pipeline Progress
Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report) and increased the price target to $75.00 from $0.00. Tyler Van Buren’s rating is based on a careful ...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's ...
STAT5d
Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
FiercePharma4d
Moderna gears up for potential RSV vaccine launch this fall after better-than-expected Q1
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...
How Moderna's cost-cutting moves hit a Bay Area biotech
As Moderna eyes expanding beyond its Covid-19 vaccine, it is prioritizing certain R&D efforts, taking cost-cutting steps and ...
FierceBiotech4d
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
The PFS ready-to-use formulation will save pharmacists and clinicians time, potentially alleviating wait times and reducing ...
Why Moderna Stock Blasted 13% Higher Today
The company notched beats on both the top and bottom lines despite a major drop-off in demand for its famous product.
FierceBiotech5d
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership ...